CellCept
Company: Roche
Approval Status: Approved February 1998
Treatment for: prevention of organ rejection inpatients undergoing heart transplants
Areas: Cardiology/Vascular Diseases; Endocrinology; Immunology/Infectious Diseases
| General Information | Side Effects |
General Information
CellCept when used in combination with cyclosporine and corticosteroids has been approved for the prevention of organ rejection inpatients undergoing heart transplants. CellCept has previously been approved for the prevention of organ rejection in kidney-transplant patients.
Side Effects
The principal adverse reactions associated with the administration of Cell Cept include diarrhea, leukopenia (reduction of white blood cells), sepsis, and vomiting, and there is evidence of a higher frequency of certain types of infections.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
